FindTrial
Sign In

Analysis of the differential effects of anti thymocyte globulin (ATG) on lymphocyte subsets in patients with severe aplastic anemia

Analysis of the differential effects of anti thymocyte globulin (ATG) on lymphocyte subsets in patients with severe aplastic anemia - ATG effects in Aplastic Anemia

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42742
Enrollment
30
Registered
2016-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe aplastic anemia

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18 years or older - Acquired aplastic anemia based on diagnosis criteria of the Dutch Guidelines for diagnosis and treatment of adult aplastic anemia - Planned treatment with ATG

Exclusion criteria

Exclusion criteria: - Severe psychological disturbances.

Design outcomes

Primary

MeasureTime frame
Number and phenotype of circulating lymphocytes before, during and after treatment with ATG—

Secondary

MeasureTime frame
Persistence and binding capacity of ATG derived antibodies—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)